Abstract
With a newly World Health Organization (WHO)–prequalified typhoid conjugate vaccine (TCV), Gavi funding for eligible countries, and a WHO policy recommendation for TCV use, now is the time for countries to introduce TCVs as part of an integrated typhoid control program, particularly in light of the increasing burden of antimicrobial resistance. Continued vaccine development efforts will lead to secure supply of low-cost vaccines, and ongoing vaccine studies will provide critical vaccine performance data and inform optimal deployment strategies, in both routine use and in outbreak settings. TCV programs should include thoughtful communication planning and community engagement to counter vaccine hesitancy.
Highlights
This is a historic moment for typhoid control
Recent multicenter surveillance studies in Africa and Asia have improved understanding of the age and geographic distribution of typhoid, demonstrating that it is an illness that affects young children as well as school age children living in both urban and rural settings [1,2,3]. These and other epidemiological data informed the recommendations by the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization in October 2017 on the use of typhoid conjugate vaccine (TCV) for typhoid control [4]
The updated 2018 WHO policy on typhoid vaccination includes a first-time recommendation for the routine use of TCVs, including in children
Summary
This is a historic moment for typhoid control. Despite continuing gaps, we have a more refined understanding of the burden of typhoid fever, as well as improved tools available to reduce the burden dramatically. These and other epidemiological data informed the recommendations by the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization in October 2017 on the use of typhoid conjugate vaccine (TCV) for typhoid control [4]. The updated 2018 WHO policy on typhoid vaccination includes a first-time recommendation for the routine use of TCVs, including in children
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
